Melanotan II Side Effects and Safety
Reported Melanotan II side effects, contraindications, and safety signals.
Safety & Contraindications
Melanotan II is a research compound and is not FDA-approved for general use. It should be avoided by anyone with atypical moles / dysplastic nevi, history of melanoma or skin cancer, cardiovascular disease, and pregnancy. Most reported effects are mild and dose-dependent, so start at the low end of the dosing range and titrate up slowly rather than chasing a maximal dose. Injection-site redness, itching, or a temporary lump are the most common local reactions; rotate sites and use clean technique to keep them minimal.
What to Monitor
Track body weight, systolic blood pressure, and diastolic blood pressure while you're running Melanotan II so you can catch any drift early and adjust before it becomes a problem. Add these to your REGEN biomarker dashboard and re-check on your normal cadence.
Contraindications
- atypical moles / dysplastic nevi
- history of melanoma or skin cancer
- cardiovascular disease
- pregnancy
References
- Melanotan II: review of melanocortin agonist effects and risks · Habbema L, et al. · 2017
- Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996;58(20):1777-84. · King KM, Davis T · 1998
- Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. · Wessells H, Levine N, Hadley ME et al. · 2000
- Evaluation of melanotan-II, a superpotent cyclic melanotropic ... · Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME · 1996
- Wessells H, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology. 1998;160(2):389-93. · Sabri O, Zimny M, Schreckenberger M, Reinartz P, Ostwald E, Buell U · 1999
- Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. · Wessells H, Gralnek D, Dorr R et al. · 2000